Back
 WJV  Vol.1 No.3 , August 2011
Immune Augmentation of Injectable PLGA – Dextran (PLDEX) a Double Polymeric Microspheres as an Adjuvant for Hepatitis B Vaccine
Abstract: A new method has been developed to prepare microspheres by blending PLGA and dextran polymers (PLDEX) using solvent evaporation technique. Recombinant hepatitis B vaccine (HBsAg) was incorporated in to the double polymeric system. The objective of this study was to investigate the feasibility of PLDEX polymeric microspheres as an adjuvant for hepatitis B vaccine (HBsAg). The present study demonstrates the immunogenicity profile of HBsAg encapsulated in PLDEX and compared their efficacy with alum adsorbed HBsAg. The single intramuscular injection of HBsAg loaded PLDEX microspheres in Wistar rats resulted satisfactory antibody titers. Based on in vivo findings PLDEX microspheres were able induce satisfactory immune response.
Cite this paper: nullS. Moni, S. Natarajapillai and M. Safhi, "Immune Augmentation of Injectable PLGA – Dextran (PLDEX) a Double Polymeric Microspheres as an Adjuvant for Hepatitis B Vaccine," World Journal of Vaccines, Vol. 1 No. 3, 2011, pp. 104-108. doi: 10.4236/wjv.2011.13011.
References

[1]   M. R. Hilleman, “Vaccines in Historic Evolution and Perspective: A Narrative Vaccine Discoveries,” Vaccine, Vol. 18, No. 15, 2000, pp. 1436-1447. doi:10.1016/S0264-410X(99)00434-X

[2]   M. A. Kane, “Global Status of Hepatitis B Immunization,” Lancet, Vol. 348, No. 9029, 1996, p. 696. doi:10.1016/S0140-6736(05)65598-5

[3]   T. Joseph and L. Stephen, “Antiviral Chemotherapy for the Treatment of Hepatitis B Virus Infection,” Gastroenterology, Vol. 118, No. 2, 2000, pp. S83-S103. doi:10.1016/S0016-5085(00)70008-4

[4]   P. R. Perrillo, W. Teresa, R. Jorge, L. Gary, S. Eugene, G. Robert, M. Paul, D. Jules, A. Paul, D. Rolland, A. Gaya, B. Steve, C. Lynn and B. Nathaniel, “A Multicenter United States—Canadian Trial to Assess Lamivudine Monotherapy before and after Liver Transplantation for Chronic Hepatitis B,” Hepatology, Vol. 33, No. 2, 2001, pp. 424-432. doi:10.1053/jhep.2001.21554

[5]   L. A. Moyer and E. E. Mast, “Hepatitis B: Virology, Epidemiology, Disease, and Prevention, and an Overview of Viral Hepatitis,” American Journal of Preventive Medicine, Vol. 10, 1994, pp. 45-55.

[6]   S. Tazio, K. M. Thomas, S. Gabriela and J. Pal, “Immunity in Response to Particulate Antigen Delivery Systems,” Advance Drug Delivery Revew, Vol. 57, No. 3, 2005, pp. 333-355. doi:10.1016/j.addr.2004.09.008

[7]   F. U. Karen, H. Roy, Z. Kim, U. M. Christina, A. Jaklenec, J. Frazier, L. Noah, B. Paul, M. K. Alexander and L. Robert, “A Potential Approach for Decreasing the Burst Effect of Protein from PLGA Microspheres,” Journal of Pharmaceutical Sciences, Vol. 92, No. 8, 2003, pp. 1582- 1591. doi:10.1002/jps.10414

[8]   I. Gutierro, R. M. Hernandez, M. Igartua, A. R. Gascon and J. L. Pedraz, “Influence of Dose and Immunization Route on the Serum IgG Antibody Response to BSA Loaded PLGA Microspheres,” Vaccine, Vol. 20, No. 17-18, 2002, pp. 2181-2190. doi:10.1016/S0264-410X(02)00146-9

[9]   J. M. Alonso, K. R. Gupta, M. Caroline, R. G. Siber and L. Robert, “Biodegradable Microspheres as Controlled— Release Tetanus Toxoid Delivery Systems,” Vaccine, Vol. 12, No. 4, 1994, pp. 299-306. doi:10.1016/0264-410X(94)90092-2

[10]   M. W. Russell, C. Lue, W. Van den Bake, Z. Moldoveanu and J. Mestecky, “Molecular Heterogenicity of Iga Antibodies during an Immune Response,” Clinical & Experimental Immunology, Vol. 87, No. 1, 1992, pp. 1-6. doi:10.1111/j.1365-2249.1992.tb06404.x

 
 
Top